Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 412

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 412
---
 with Rule 14a-8 under the Exchange Act.

### OTHER STOCKHOLDER COMMUNICATIONS
Stockholders and interested parties may communicate with the Iris Board, any committee chairperson or the non-management directors as a group by writing to the Iris Board or committee chairperson in care of Iris Acquisition Corp, 3rd Floor Zephyr House 122 Mary Street, George Town, P.O. Box 10085, Grand Cayman KY1-1001, Cayman Islands, Attention: Sumit Mehta. Following the Business Combination, such communications should be sent in care of Liminatus Pharma, Inc., 6 Centerpointe Drive, Suite 625, La Palma, CA 90623, Attention: CEO. Each communication will be forwarded, depending on the subject matter, to the ParentCo Board, the appropriate committee chairperson or the non-management directors.

<div align='center'>227</div>

TABLE OF CONTENTS

### WHERE YOU CAN FIND MORE INFORMATION
Iris files reports, proxy statements and other information with the SEC as required by the Exchange Act. You may access information on Iris at the SEC web site containing reports, proxy statements and other information at: http://www.sec.gov.

If you would like additional copies of this proxy statement/prospectus or if you have questions about the Business Combination, you should contact via phone or in writing:

<div align='center'>Alliance Advisors, LLC 
 200 Broadacres Drive, 3rd Floor 
 Bloomfield, New Jersey 07003 
 Toll Free: 844-670-2141 
 Email: IRAA@allianceadvisors.com</div>

You may also obtain these documents by requesting them via e-mail from IRAA@allianceadvisors.com. If you are a stockholder and would like to request documents, please do so no later than five business days before the Special Meeting in order to receive them before the Special Meeting. If you request any documents from us, we will mail them to you by first class mail, or another equally prompt means.

All information contained in this proxy statement/prospectus relating to Iris has been supplied by Iris, and all such information relating to Liminatus has been supplied by Liminatus. Information provided by either Iris or Liminatus does not constitute any representation, estimate or projection of the other.

This document is a proxy statement of Iris for the Special Meeting. Iris has not authorized anyone to give any information or make any representation about the Business Combination, Iris or Lim